🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Regorafenib for Hepatocellular Carcinoma in Real-World Practice (REFINE) Liver Cancer doi.org/10.1159/000542… 🔎 Prospective, Observational Study, 1.005 pts 👉mOS 13.2 mo 👉mOS ALBI 1: 20; ALBI 2: 10 mo; ALBI 3: 4mo 🧐No surprises... ESMO - Eur. Oncology EASL Education ILCA #livertwitter

➡️ Check out our manuscript just published in AmericanJournalofHematology on Treated Secondary-AML: 673 patients, largest reported cohort 🔴 High-risk subtype: outcomes dismal, even in rare patients with fav genomics ✅ Warrants an independent prognostic designation 🔵 Ven improves outcomes in

#hematology #oncologyboards cHL early favorable treatment algorithm

#hematology #oncologyboards cHL stage I/IIB unfavorable algorithm.

#CDmarkers #hemeboards CLL is positive for CD5 and CD 23(2+3=5) Whereas Mantle cell is negative for both.

#GI25 highlights #CommunityOnc: 1. #SCIENCE: Adv Eso SCC 2. #ESOPEC publication (Eso/GEJ/Ga) 3. Chemo in resectable Panc Ca 4. #StarterNET: GEP-NET 5. #CM8HW: dMMR/MSI-H mCRC 6. #BREAKWATER: BRAFV600E mCRC 7. ctDNA: #BESPOKE + SWOG80702 #OncTwitter #gism ASCO 1/8

🧵 Many “hot takes” about the reduction of NIH indirect grant costs to 15%. Let’s lay out the facts about the university grant management process & accounting. And then use this to project likely short and longer term impacts of the policy.

A great review on prostate cancer Treatment algorithm👇 jamanetwork.com/journals/jama/…

Management of APS in pregnancy. #hemeboards

Treatment Algorithm: This is the algorithm we’ve used during our discussion w/ Emil Lou, MD, PhD, FACP on #PancreaticCancer #OncTwitter #MedTwitter #gism CancerNetwork® OncoAlert

Ipi/Nivo now FDA Oncology approved based off #Checkmate8HW: Ph 3, dMMR/MSI-H mCRC, Ipi (1mg/kg) + Nivo (240mg) Q3W for 4 cycles and then Nivo alone vs Nivo: - mPFS NR for Ipi/Nivo vs 39·3 months - ORR: 71% vs 58% - Any grade AEs 81% from Ipi/Nivo vs 71% Nivo alone. #OncTwitter

Great discussion on pancreatic cancer by my fabulous mentor Dr. Lou ⁦Emil Lou, MD, PhD, FACP⁩ and ⁦Oncology Brothers⁩ podcasts.apple.com/us/podcast/onc…

Breaking News! (Quite literally 😍) #ASCO25 🚨 BREAKWATER trial (NEJM): EC + mFOLFOX6 sets new 1L standard in BRAF V600E-mutant mCRC ➡️OS: 30.3 vs 15.1 mo (HR 0.49, P<0.001) ➡️PFS: 12.8 vs 7.1 mo (HR 0.53, P<0.001) ⚠️ Grade ≥3 AEs: 46.1% vs 38.9% — manageable, consistent with

#ASCO25 #TTDUpdates Perioperative Durvalumab in Gastric and Gastroesophageal Junction Cancer nejm.org/doi/abs/10.105… ✅2y EFS 67.4% vs 58.5% ✅2y OS 75.4% vs 70.4% ✅PCR 19.2% vs 7.2% ✅no difference AEs grade 3-4 or delay surgery FLOT durvalumab new SOC perioperative GC/GEJ

📢 On June 3, 2025, Darolutamide received its FDA approval for de novo metastatic castration-sensitive prostate cancer (mCSPC). To mark this milestone, we created this comprehensive infographic: ✅ All modern AR pathway inhibitors now approved for mCSPC 📉 10-year FDA timeline

Just out! New IMS/ IMWG Definition of High Risk Myeloma. Journal of Clinical Oncology #IMWG25 Myeloma Society International Myeloma Foundation Nikhil C. Munshi, MD marivi mateos Sagar Lonial MD Saad Z. Usmani MD MBA FACP 🇺🇸🇵🇰 Noopur Raje

Congratulations to Gaurav Sharma, MD Dr. Gaurav Sharma who is completing his heme-onc fellowship this month USA Mitchell Center! Paper on uncovering IO biomarkers for anal cancers - published today ESMO Open sciencedirect.com/science/articl…

“What an honor to receive the Dundie Award for Best Fellow!”